Marco Mazzoletti
Pfizer (Italy)(IT)
Publications by Year
Research Areas
PI3K/AKT/mTOR signaling in cancer, Bone health and treatments, Protein Kinase Regulation and GTPase Signaling, Synthesis of Organic Compounds, Cell death mechanisms and regulation
Most-Cited Works
- → Cancer-derived p53 mutants suppress p53-target gene expression--potential mechanism for gain of function of mutant p53(2007)142 cited
- → Phospholipase Cγ1 Is Required for Metastasis Development and Progression(2008)138 cited
- → Combined inhibition of Chk1 and Wee1: In vitro synergistic effect translates to tumor growth inhibition in vivo(2012)113 cited
- → Combination of PI3K/mTOR Inhibitors: Antitumor Activity and Molecular Correlates(2011)79 cited
- → A novel inhibitor of the PI3K/Akt pathway based on the structure of inositol 1,3,4,5,6-pentakisphosphate(2010)52 cited
- → Insight into the neuroproteomics effects of the food-contaminant non-dioxin like polychlorinated biphenyls(2012)51 cited
- → PI3K/AKT/mTOR Inhibitors In Ovarian Cancer(2010)42 cited
- → HtrA2 enhances the apoptotic functions of p73 on bax(2008)29 cited
- → Preclinical Colorectal Cancer Chemopreventive Efficacy and p53-Modulating Activity of 3′,4′,5′-Trimethoxyflavonol, a Quercetin Analogue(2010)25 cited
- → 264TiP TACTIVE-K: Phase Ib/II study of vepdegestrant, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, in combination with PF-07220060, a cyclin-dependent kinase (CDK)4 inhibitor, in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer(2024)3 cited